SEGMENTS

We manage our operations in two reportable segments, pharmaceutical and diagnostics. The pharmaceutical segment consists of our pharmaceutical operations we acquired in Chile, Mexico, Ireland, Israel and Spain and our pharmaceutical research and development. The diagnostics segment primarily consists of our clinical laboratory operations we acquired through the acquisitions of BioReference and OPKO Lab and our point-of-care operations. There are no significant inter-segment sales. We evaluate the performance of each segment based on operating profit or loss. There is no inter-segment allocation of interest expense and income taxes.

Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows:



	For the three months ended June 30,						For the six months ended June 30,
(In thousands)	2017			2016			2017			2016
Revenue from services:
Pharmaceutical	$	—		$	—		$	—		$	—
Diagnostics	256,671			266,012			511,956			518,534
Corporate	—			—			—			—
	$	256,671		$	266,012		$	511,956		$	518,534
Revenue from products:
Pharmaceutical	$	28,966		$	22,807		$	51,197		$	42,706
Diagnostics	—			—			—			—
Corporate	—			—			—			—
	$	28,966		$	22,807		$	51,197		$	42,706
Revenue from transfer of intellectual property:
Pharmaceutical	$	28,576		$	68,281		$	47,154		$	86,898
Diagnostics	—			—			—			—
Corporate	—			—			—			—
	$	28,576		$	68,281		$	47,154		$	86,898
Operating income (loss):
Pharmaceutical	$	(8,621	)	$	35,345		$	(31,258	)	$	34,015
Diagnostics	(4,944		)	10,374			(8,044		)	8,019
Corporate	(12,878		)	(17,453		)	(28,849		)	(41,286		)
	$	(26,443	)	$	28,266		$	(68,151	)	$	748
Depreciation and amortization:
Pharmaceutical	$	6,694		$	2,987		$	13,469		$	5,848
Diagnostics	18,827			21,573			37,752			40,893
Corporate	30			20			60			39
	$	25,551		$	24,580		$	51,281		$	46,780
Income (loss) from investment in investees:
Pharmaceutical	$	(5,309	)	$	391		$	(7,123	)	$	(4,430	)
Diagnostics	(319		)	(2,379		)	(635		)	97
Corporate	—			—			—			—
	$	(5,628	)	$	(1,988	)	$	(7,758	)	$	(4,333	)
Revenues:
United States	$	266,874		$	266,044		$	522,514		$	518,482
Ireland	21,913			71,789			42,630			93,932
Chile	11,899			9,597			22,020			16,580
Spain	5,118			4,324			9,623			8,347
Israel	7,654			4,420			11,872			9,162
Mexico	724			926			1,589			1,635
Other	31			—			59			—
	$	314,213		$	357,100		$	610,307		$	648,138



(In thousands)	June 30, 2017		December 31, 2016
Assets:
Pharmaceutical	$	1,294,645	$	1,294,916
Diagnostics	1,380,849		1,408,522
Corporate	93,200		63,181
	$	2,768,694	$	2,766,619
Goodwill:
Pharmaceutical	$	259,288	$	251,817
Diagnostics	452,787		452,786
Corporate	—		—
	$	712,075	$	704,603

One customer represented more than 10% of our total consolidated revenue during the three and six months ended June 30, 2017. As of June 30, 2017, no customer represented more than 10% of our accounts receivable balance. As of December 31, 2016, one customer represented more than 10% of our accounts receivable balance.